1. Patient and Clinician Perspectives on Preventive Therapy for Migraine

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Prevalence of Migraine

6. Migraine History

7. Diagnosing Migraine

8. CM and Medication Overuse

9. Risk Factors Associated With Progression of CM

10. How Does Chronification of Migraine Occur?

11. Preventive Treatment

12. What Is CGRP and What Role Does It Play in Migraine?

13. CGRP Receptor Complex

14. Anti-CGRP Monoclonal Antibodies in Development

15. Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Eptinezumab for Prevention of CM

16. Phase 3 REGAIN Study of Galcanezumab in Patients With CM

17. Early Results of Phase 3 HALO Trial for Fremanezumab

18. Phase 2: Prevention of CM With Erenumab

19. Conclusion

20. Questions?

21. Abbreviations

22. Abbreviations (cont)